新日本製薬(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証PRM | 化学 | 4931/ - | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2020/01/31 | 日証協 | 325,700株 | +25.8% | 234,600株 | +149.04% | 268,251株 | +16.76% | 64,116株 | +27.72% |
2020/01/24 | 日証協 | 258,900株 | +29.84% | 94,200株 | +43.6% | 229,743株 | +11.61% | 50,200株 | +68.89% |
2020/01/17 | 日証協 | 199,400株 | -2.54% | 65,600株 | -15.46% | 205,852株 | -2.54% | 29,723株 | -57.73% |
2020/01/10 | 日証協 | 204,600株 | +14.17% | 77,600株 | 0% | 211,215株 | +18.25% | 70,314株 | +904.49% |
2019/12/30 | 日証協 | 179,200株 | -0.61% | 0株 | -100% | 178,615株 | +0.28% | 7,000株 | -79.17% |
2019/12/27 | 日証協 | 180,300株 | +23.07% | 62,300株 | +476.85% | 178,115株 | -9.18% | 33,601株 | +12.74% |
2019/12/20 | 日証協 | 146,500株 | -9.68% | 10,800株 | -57.98% | 196,109株 | -3.87% | 29,805株 | +22.15% |
2019/12/13 | 日証協 | 162,200株 | -1.16% | 25,700株 | -28.01% | 204,009株 | +4.19% | 24,400株 | +64.86% |
2019/12/06 | 日証協 | 164,100株 | +29.31% | 35,700株 | -8.7% | 195,809株 | +1.87% | 14,800株 | -39.34% |
2019/11/29 | 日証協 | 126,900株 | +18.16% | 39,100株 | +96.48% | 192,209株 | +6.19% | 24,400株 | +103.33% |
2019/11/22 | 日証協 | 107,400株 | +0.37% | 19,900株 | +158.44% | 181,009株 | -1.84% | 12,000株 | -69.85% |
2019/11/15 | 日証協 | 107,000株 | -43.92% | 7,700株 | -82.22% | 184,409株 | -21.28% | 39,800株 | +167.11% |
2019/11/08 | 日証協 | 190,800株 | -3.54% | 43,300株 | -81.26% | 234,246株 | -1.97% | 14,900株 | -84.32% |
2019/11/01 | 日証協 | 197,800株 | -20.4% | 231,100株 | +45.44% | 238,946株 | -18.04% | 95,001株 | +68.43% |
2019/10/25 | 日証協 | 248,500株 | +1.59% | 158,900株 | -39.63% | 291,545株 | +10.71% | 56,405株 | +28.19% |
2019/10/18 | 日証協 | 244,600株 | +1.16% | 263,200株 | +22.08% | 263,340株 | +1.5% | 44,000株 | +12.53% |
2019/10/11 | 日証協 | 241,800株 | -28.88% | 215,600株 | +2.42% | 259,440株 | -25.91% | 39,101株 | -63.32% |
2019/10/04 | 日証協 | 340,000株 | +109.88% | 210,500株 | +230.97% | 350,177株 | +83.65% | 106,600株 | -46.64% |
2019/09/27 | 日証協 | 162,000株 | +29.08% | 63,600株 | +123.16% | 190,677株 | +5.95% | 199,777株 | +538.27% |
※株式分割は考慮していませんのでご注意ください。
Page Top